Sleep Disordered Breathing Is Highly Prevalent in Patients with Lung Cancer: Results of the Sleep Apnea in Lung Cancer Study

Obstructive sleep apnea (OSA) has been linked to tumorigenesis and tumor progression. The Sleep Apnea in Lung Cancer (SAIL) study (NCT02764866) was designed to determine the prevalence of OSA in patients with lung cancer. Cross-sectional study including consecutive patients with newly diagnosed lung...

Full description

Saved in:

Bibliographic Details
Published in:	Respiration Vol. 97; no. 2; p. 119
Main Authors:	Cabezas, Elena, Pérez-Warnisher, M Teresa, Troncoso, Maria Fernanda, Gómez, Teresa, Melchor, Rosario, Pinillos, Erwin Javier, El Hachem, Abdul, Gotera, Carolina, Rodríguez, Paula, Mahillo Fernández, Ignacio, Martínez-García, Miguel Ángel, Peces-Barba, German, Seijo, Luis M
Format:	Journal Article
Language:	English
Published:	Switzerland 01-01-2019
Subjects:	Adenocarcinoma - complications Aged Carcinoma, Small Cell - complications Carcinoma, Squamous Cell - complications Cross-Sectional Studies Female Humans Hypoxia - complications Lung Neoplasms - complications Male Prospective Studies Pulmonary Disease, Chronic Obstructive - complications Severity of Illness Index Sleep Apnea Syndromes - complications Lung cancer Sleep apnea Sleep disordered breathing
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Obstructive sleep apnea (OSA) has been linked to tumorigenesis and tumor progression. The Sleep Apnea in Lung Cancer (SAIL) study (NCT02764866) was designed to determine the prevalence of OSA in patients with lung cancer. Cross-sectional study including consecutive patients with newly diagnosed lung cancer. All patients were offered home sleep apnea testing (HSAT) and administered a sleep-specific questionnaire prior to initiating oncologic treatment. Sleep study-related variables, symptoms, and epidemiologic data as well as cancer related variables were recorded. Eighty-three patients were enrolled in the SAIL study. Sixty-six completed HSAT. The mean age was 68 ± 11 years and 58% were male with a mean body mass index of 28.1 ± 5.4. Forty-seven percent were current smokers, 42% former smokers, and 11% never smokers with a median tobacco consumption of 51 pack-years. Fifty percent had COPD with a mean FEV1 of 83 ± 22.6% of predicted and a mean DLCO of 85.5 ± 20.1%. Adenocarcinoma was the most common histologic type (46.7%), followed by squamous cell (16.7%) and small cell (16.7%). Most patients were diagnosed at an advanced stage (65% in stages III-IV). The vast majority (80%) had OSA (apnea-hypopnea index [AHI] > 5), and 50% had moderate to severe OSA (AHI > 15) with a mean Epworth Sleepiness Score of 7.43 ± 3.85. Significant nocturnal hypoxemia was common (Median T90: 10.9% interquartile range 2.4-42.2). Sleep apnea and nocturnal hypoxemia are highly prevalent in patients with lung cancer.
ISSN:	1423-0356
DOI:	10.1159/000492273